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Abstract
Respiratory viral infections contribute substantially to global infant losses and disproportion-
ately affect preterm neonates. Using our previously established neonatal murine model of
influenza infection, we demonstrate that three-day old mice are exceptionally sensitive to
influenza virus infection and exhibit high mortality and viral load. Intranasal pre- and post-
treatment of neonatal mice with Lactobacillus rhamnosus GG (LGG), an immune modulator
in respiratory viral infection of adult mice and human preterm neonates, considerably
improves neonatal mice survival after influenza virus infection. We determine that both live
and heat-killed intranasal LGG are equally efficacious in protection of neonates. Early in
influenza infection, neonatal transcriptional responses in the lung are delayed compared to
adults. These responses increase by 24 hours post-infection, demonstrating a delay in the
kinetics of the neonatal anti-viral response. LGG pretreatment improves immune gene tran-
scriptional responses during early infection and specifically upregulates type I IFN path-
ways. This is critical for protection, as neonatal mice intranasally pre-treated with IFNβ
before influenza virus infection are also protected. Using transgenic mice, we demonstrate
that the protective effect of LGG is mediated through a MyD88-dependent mechanism, spe-
cifically via TLR4. LGG can improve both early control of virus and transcriptional respon-
siveness and could serve as a simple and safe intervention to protect neonates.
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Author summary
Viral lung infections are the number one reason for hospitalization of children under the
age of 5 and are a major public health concern. Premature babies, or those born before 37
weeks gestation, are particularly susceptible to viral infections, but exact mechanisms for
this susceptibility have not been determined. Here, using a pre-clinical infant mouse
model of influenza virus infection, we have found increased neonatal susceptibility to
respiratory viral infection compared to adults, and we demonstrate that a probiotic
administered intranasally prior to infection provides dramatic protection to infant mice
by inducing production of a key anti-viral cytokine, type I interferons.
Introduction
Respiratory infection in preterm and term neonates is a major public health problem. Respira-
tory syncytial virus (RSV) bronchiolitis is the leading cause of infant hospitalization in the
United States annually [1], and globally, influenza virus causes approximately 374,000 respira-
tory hospitalizations per year in children <1 y of age (including 270,000 among those less than
6 months) [2]. The most significant risk factors for hospitalization due to an acute lower respi-
ratory tract infection are prematurity and age [3]. Late preterm infants have significantly
higher risk for respiratory disease and infections, which contributes to the use of twice as
many healthcare dollars over the first 2 years of life, as compared to their term counterparts
[4].
During this critical window of susceptibility to viral infection, neonates begin to be colo-
nized with a variety of microbiota which are molded into niche-specific bacterial communities
[5, 6]. These commensal communities are highly dynamic during the first few months of life
for preterm and term neonates and are impacted by external factors, such as antibiotic expo-
sure, mode of neonatal delivery and diet [7]. Differences in the dominant airway microbial
communities in these first few months of life has been linked to susceptibility to respiratory
infections [8]. In addition, commensal-derived signals establish an activation threshold of the
innate immune system required for optimal antiviral immunity [9]. Therefore, modulating
early airway microbial communities presents a potential therapeutic strategy to prevent or
ameliorate respiratory tract infections. Indeed, local treatment in the form of intranasal
administration of Lactobacillus rhamnosus GG (LGG) [10] and Lactobacillus casei [11, 12] to
adult mice significantly reduces the symptoms and increased survival rates in influenza virus-
infected mice.
Clinical epidemiologic observations further suggest that the immune effects of early-life
microbial exposure persist into later life [13]. Similarly, the murine microbiome can influence
anti-viral immunity against influenza infection [14]. The use of multiple doses of intranasal
probiotics augments the immune response of adult mice infected with influenza virus and
RSV, demonstrating their protective role in the context of viral infections [15–19]. Clinical
studies suggest that oral LGG might protect children from influenza virus infection through
an interaction with gut-associated immune tissue by indirectly up-regulating respiratory
immunity [20–22].
To date, investigation of probiotic treatments to protect the host from respiratory infections
have used oral administration, which presumably acts systemically [15–19]. We hypothesized
that intranasal LGG would provide neonatal mice with protection from the sequelae of influ-
enza virus infection. To test this hypothesis, we used our previously established murine model
of neonatal influenza virus infection [23] to investigate neonatal susceptibility to respiratory
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viral infection and determine whether intranasal LGG treatment prior to infection provides
protection. Probiotics may accelerate antiviral protection by stimulating the production of
type I Interferons (IFNs) [12, 24, 25]. We demonstrate here that 3-day old mice are exception-
ally susceptible to influenza virus infection and have minimal transcriptional responses to the
infection at 12 hours post-infection, which begins to improve by 24 hours post-infection, dem-
onstrating a delay in the kinetics of the neonatal antiviral response. Administration of LGG
prior to influenza infection dramatically improves survival and provides an early increase in
transcription of type I IFNs. This LGG-mediated protection is MyD88-dependent and specifi-
cally involves TLR4 recognition of LGG.
Results
Neonatal mice are highly susceptible to influenza virus
We have previously described a reduced and delayed primary CD8+ T cell response to
influenza virus in 3-day old neonatal mice [23]. Using our established neonatal infection
model, 3-day old and 8-week old adult C57BL/6 mice were infected with H1N1 influenza
virus strain A/Puerto Rico/8/1934 (PR8) and followed for morbidity and mortality. Three-
day old mice were exquisitely sensitive to influenza virus infection and exhibited high mor-
tality. When 3-day old mice were infected with the same weight-adjusted dosage of PR8
virus (0.15 TCID50 /g weight) as adults, 100% succumbed within 8 days (Fig 1A). When
neonatal mice were infected with a four-fold lower dose of PR8 influenza virus than their
adult counterparts (0.04 TCID50 /g versus 0.15 TCID50/g, for neonate and adult mice
respectively), only 20% of neonates survived by 7 days post-infection. Ultimately, only 10%
of neonates survived this low-dose challenge, while 100% of adults survived a standard
dose challenge (Fig 1B). Despite the much lower infecting dose, neonatal mice have pro-
foundly increased mortality, particularly between 5 and 8 days post-infection compared to
adult mice.
With this early mortality, we asked whether there were differences in viral load early in
infection. Neonatal animals were infected and harvested at 1, 3, and 6 days post-infection.
Viral loads were significantly higher in neonatal animals as compared to adult animals at 1 day
(p<0.01) and 3 days post-infection (p<0.02) (Fig 1C), but were similar to adult animals by 6
days post-infection, suggesting that neonates fail to respond to viral infection during early
stages of infection.
Fig 1. Decreased survival of influenza virus-infected neonatal mice coupled with loss of early viral control. 3-day old
neonatal and 8 week-old adult mice were intranasally infected with PR8 influenza virus. (A) Neonates were infected with the
same sublethal adult virus dose. Neonatal mice (n = 8) and adult mice (n = 4) from 2 independent experiments. (B) Neonates
were infected with one fifth of a sublethal adult virus dose. Neonatal mice (n = 24) and adult mice (n = 6) from 3 independent
experiments. (C) 3-day old neonatal and 8 week-old adults mice were intranasally infected with the same dose of influenza virus
as (B). Mice were harvested at 1, 3, and 6 days post-infection shown. Viral loads in lungs were measured by RT-PCR.
https://doi.org/10.1371/journal.ppat.1008072.g001
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Treatment with LGG prior to influenza infection protects neonatal mice
Lactobacillus species have shown promise as immune adjuvants in viral infections in adult ani-
mal models [14, 26, 27]. Based on our observation of limited and delayed neonatal responses
to viral infection (Fig 1B and 1C), we asked whether probiotic administration of LGG could
protect neonatal mice. On Days 1 and 2 of life, neonatal mice were given 2 separate intranasal
doses of 1x106 colony forming units (CFU) of live LGG or similarly diluted Lactobacilli MRS
growth media as a sham control (Sham). Both groups of mice were then infected with the
same dose (0.04TCID50 /g) of PR8 influenza virus on Day 3 of life. We chose to treat mice
intranasally with LGG to directly apply LGG to the respiratory mucosa. Furthermore, we
chose a brief, two-day course for the practical reason that the mouse immune system rapidly
changes in the first week of life [23], compared to adult murine studies where probiotics are
given over several weeks [26, 28]. We found that intranasal administration of LGG on the first
and second day of life prior to influenza infection profoundly improved survival, with 65% of
the pups surviving who received the probiotic (LGG), as compared to only 10% survival of
pups receiving sham treatment (Sham) (p<0.01) (Fig 2A).
Others have found that intranasal application of LGG prior to influenza infection in adult
mice is protective, but this requires a multi-dose protocol over a 3–4 week period, using 10–
Fig 2. Improved survival and decreased viral loads of neonatal mice when pretreated with Lactobacillus prior to Influenza infection.
(A) Mouse pups received 1 x106 Colony Forming Units of LGG intranasally on Days 1 and 2 of life. On Day 3, pups were infected
intranasally with PR-8 influenza, and survival was monitored. n = 15 per group from 3 independent experiments. (B) To test if LGG
protected older infant mice, mouse pups were given 1.5 x106 Colony Forming Units of LGG intranasally on Day 6 of life. On Day 7, pups
were infected intranasally with PR8 influenza, and survival was monitored. n = 14 per group from 3 independent experiments. To test if
LGG conferred protection after influenza infection, mice were infected on the third day of life with influenza. (C) 24 hours or (D) 48
hours later, mice were given 1 x106 Colony Forming Units of LGG intranasally. n = 16 per group from 4 independent experiments. (E)
Viral loads were determined at 3 and 6 days post infection by real time PCR. Data from 3 independent experiments. Real time PCR was
performed to determine transcription of (F) IFNγ and (G) IL-6 at 3 days post-infection. Data from 4 independent experiments.
https://doi.org/10.1371/journal.ppat.1008072.g002
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100 times more CFU per dose than our treatment [10, 29]. Potentially, slightly older neonatal
mice may not have the additional benefit from a single dose of LGG, compared to 3-day old
mice, which have minimal respiratory tract microbial colonization. To test this, we pretreated
6-day old neonatal mice and infected the animals at Day 7 of life with a 0.04 TCID50/g dose.
Although mice at this age were not as sensitive to influenza as 3-day old mice, a single dose
(1.5 million CFU) of live LGG given at Day 6 of life and 1 day before influenza virus infection
was still protective (p<0.05) (Fig 2B). These results demonstrate that sensitivity to influenza
virus infection is age-dependent in neonatal mice with ~10–20% survival of 3-day old mice
increasing to ~60% for 7-day old mice and 100% for adult mice. These results also reveal that
intranasal LGG administration clearly provides protection to neonatal mice from a respiratory
infection and this protection is still afforded at 1 week of age in this infection model.
Timing of administration of intranasal LGG is critical for protection
Next, we asked whether LGG administration after influenza infection could confer similar
degrees of protection. Animals were infected on Day 3 of life and then received a dose of live
LGG 24 hours (Fig 2C) or 48 hours (Fig 2D) after infection. When LGG was administered 24
hours after infection, there was a statistically significant improvement in survival between
those animals receiving the LGG and those receiving sham treatment (p<0.01). Although the
difference in survival was smaller than when LGG was administered prior to infection, it still
conferred a 4.5-fold increase in survival. When animals received LGG 48 hours post-infection,
protective benefits of LGG treatment were lost (p = 0.27), indicating a narrow time window
within the post-infection period for LGG to be effective.
Neonates pre-treated with LGG have low influenza viral loads and low
levels of pro-inflammatory cytokines
To further understand the mechanism by which LGG protects neonates, we asked whether
LGG treatment reduced viral loads, since neonatal mice exhibited impaired viral control com-
pared to adult mice (Fig 1C). We infected LGG-treated 3-day old neonatal pups with PR8
influenza virus and compared their lung viral loads to sham-treated 3-day old neonatal pups
and adult mice. In agreement with our results above, at 3 days post-infection (DPI), sham-
treated 3-day old neonatal pups had significantly higher viral loads than sham-treated adult
mice (p<0.02) (Fig 2E). Furthermore, LGG-treated pups had lower viral loads compared to
sham-treated pups (p<0.02), comparable to viral loads in adult controls (Fig 2E). As shown
above (Fig 1C), by 6 DPI no differences in viral load were found between the LGG-treated
mice and the sham-treated pups and adults. Therefore, neonatal pups that received LGG had
better control of viral infection at early time points. We next asked whether LGG-treated neo-
natal animals had less induction of pro-inflammatory cytokines because of the decreased early
viral loads. We performed real-time PCR on whole lungs to determine transcription levels of
both IFNG (Fig 2F) and IL6 (Fig 2G) and found these levels to be reduced in neonatal pups
treated with LGG compared to sham-treated pups (p<0.03).
Neonatal pups pretreated with LGG have similar pathology severity scores
In addition to massively improved survival of pups pre-treated with LGG, mortality was also
delayed (Fig 2A). Therefore, we asked whether lung pathology differed early in infection with
LGG pre-treatment, which could contribute to improved survival in the first week of infection.
Lung histopathology from pups pretreated with LGG was performed and compared to sham-
treated pups. A weighted scoring system was used [30], which accounts for both the intensity
of pathology and the percentage of lung affected. Animals were scored on the severity of
Influenza virus infected neonates are protected by intranasal Lactobacillus rhamnosus GG treatment
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alveolitis and peribronchiolitis and the percentage of affected lung in each of these respective
categories by a pathologist blinded to the treatment groups. At 3 and 6 DPI, neonates pre-
treated with LGG had similar broncho-pneumonia and clinical severity scores, compared to
neonatal animals given the sham treatment (Fig 3A and 3B). Although surprising, pathomor-
phological features do not always reflect disease severity or outcome during an early influenza
infection [31].
Next, we asked whether LGG pre-treatment resulted in differential recruitment of impor-
tant innate immune cell populations into the airway and the site of infection. Therefore, we
pretreated pups with LGG and infected with influenza virus and harvested at 1, 3 and 6 DPI.
To determine the impact of LGG alone on immune cell recruitment, we also treated with LGG
and harvested the animals at 3-days of life, the time of influenza virus infection. In whole lung,
there were no significant differences in the alveolar macrophages (CD11c+SiglecF+) or the
recruitment of neutrophils (CD11b+Ly6G and dendritic cells (CD11c+MHCHi) between LGG-
and sham-treated animals (Fig 3C), which is consistent with the pathology results (Fig 3A).
However, we did observe significant differences in the infiltration of neutrophils and dendritic
cells into the airways, as determined by bronchoalveolar lavage, consistent with previous
results[32]. No changes in alveolar macrophages were detected. (Fig 3D). Recruitment of neu-
trophils increased 10-fold with LGG alone in the absence of influenza infection at 0 days post-
infection (p<0.05), but strikingly, no change was observed in sham-treated infected animals at
Fig 3. Differential recruitment of immune cells to the alveolar airspace in neonatal animals. Mouse pups received
1 x106 Colony Forming Units of LGG intranasally on Days 1 and 2 of life. On Day 3, pups were infected intranasally
with PR-8 influenza. (A) Histopathology was done at 3 and 6 days post-infection, which demonstrated similar
bronchopulmonary infiltrates in both sham and LGG treated neonates. H&E Stain, representative figures. Arrows
indicate areas of bronchopulmonary infiltration. Clinical severity scoring was performed (B). In separate experiments,
cell counts for the specified cell types from (C) whole lung tissue and (D) bronchoalveolar lavage was determined by
flow cytometry. Data from 3 independent experiments.
https://doi.org/10.1371/journal.ppat.1008072.g003
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1 or 3 days post-infection compared to uninfected animals (Day 0) (Fig 3C and 3D). Recruit-
ment of neutrophils to the alveolar airspace is correlated with a favorable outcome in mild and
severe influenza A strains including PR8[33]. In contrast, adults have increased neutrophil
recruitment to the alveolar airspace between 1 and 3 days of infection. LGG-treated animals
show an intermediate recruitment of neutrophils (Fig 3D). All together, these results highlight
how LGG pre-treatment provides an adult-like immune phenotype to neonates.
LGG-treated neonates exhibit an adult-like transcriptional signature in the
lungs compared to sham-treated counterparts
We next investigated how LGG treatment prior to influenza virus infection mediated early
immune responses in neonates. We measured RNA transcriptional changes in 753 immune-
related genes by Nanostring technology in neonatal (LGG- and sham-treated), and adult
whole lungs 12 hours after PR8 influenza virus infection, and uninfected age-matched neo-
nates. These four experimental groups were normalized to their own housekeeping genes.
Notably, transcriptional signatures of sham-treated infected neonates clustered with those of
uninfected neonates, while the LGG-treated influenza infected neonates were more similar to
adults, with both groups showing strong induction of many immune-related genes (Fig 4A).
We next defined sets of differentially expressed genes in the three experimental groups (Sham,
LGG, and Adult) compared to untreated uninfected controls (Uninfected). Sham-treated neo-
nates infected with influenza virus had only 16 differentially expressed genes in the lungs, com-
pared to uninfected neonates. In contrast, adult mice had 414 differentially expressed genes
compared to uninfected neonates of the 753 tested (55%). Similarly, LGG-treated influenza
infected neonatal lungs had 278 differentially expressed genes of the 753 tested (37%) com-
pared to uninfected neonates; 194 of these genes were induced by more than 2-fold (S1 Table).
Therefore, the transcriptional unresponsiveness to influenza virus infection in neonatal lungs
was improved by LGG pretreatment. Indeed, of the 278 differentially expressed genes in LGG-
treated neonates, 215 were also induced in adults (Fig 4B, S2 Table), whereas sham-treated
infected neonates at 12 hours post-infection had highly similar transcriptional profiles to unin-
fected neonatal animals.
To define the key pathways induced in LGG-treated neonates, we applied canonical path-
way analysis with Ingenuity Pathway Analysis (IPA) based on the 215 genes defined above (Fig
4C). The top canonical pathways included several related to innate pathogen recognition,
notably two: “Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses”
and “Dendritic Cell Maturation”. The top upstream regulators defined by this analysis were
IFNG, LPS, STAT1, IFNAR and IL4 (Fig 4D). These transcriptional changes indicate that neo-
natal mice have a reduced early transcriptional response to influenza virus infection. Further-
more, LGG pre-treatment primed neonates to respond to influenza virus infection more like
adults and primarily increased early IFN responses at 12 hours post-infection.
Neonates have a delayed recognition and response to influenza virus
infection
Given the neonatal transcriptional paralysis to influenza infection at 12 hours post-infection,
we asked whether this paralysis persisted later in infection by comparing transcriptional
changes in neonatal whole lungs 24 hours after PR8 influenza virus infection to age-matched
uninfected neonates. To determine the impact of LGG pre-treatment alone on transcription,
we also measured transcriptional induction of immune-related genes by including LGG-
treated, uninfected neonates and LGG-treated, infected neonates at 24 hours. Similar to the
12-hour time point, sham-treated and uninfected neonates freely clustered, as did LGG-
Influenza virus infected neonates are protected by intranasal Lactobacillus rhamnosus GG treatment
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infected neonates and LGG-uninfected neonates (Fig 5A). Principal component analysis of
both 12-hour and 24-hour time points also indicated little variation between the uninfected
and infected neonates at both time points, which potentially indicates a developmentally-regu-
lated transcriptional response (Fig 5B). There was also little variation among the animals
which received the LGG alone and those animals which received LGG and were infected with
influenza virus. Therefore, most of the immune-related transcriptional changes in the LGG-
treated infected neonates was driven by LGG and not the infection. Adults distinctly separated
away from the neonates (S1 Fig), which again supports a developmental regulation.
LGG treatment alone is responsible for induction of inflammatory genes
Next, we sought to identify differentially expressed genes due to influenza virus infection or
LGG treatment alone compared to uninfected neonates at 24 hours. More immune-related
Fig 4. Lactobacillus causes differential transcriptional response to influenza. Neonatal animals were given either LGG or
sham treatment, and then infected with influenza on the third day of life. Animals were harvested 12 hours post-infection.
Nanostring gene transcription analysis was performed on lungs. (A) Heatmap of all genes test in the LGG treated neonates,
compared to expression in the other groups. Green: Upregulated; Brown: Down regulated. N = 3–4 per group, 2
experiments. (B) Venn diagram depicting the overlap of differentially regulated genes in the adult and the LGG-treated
neonate. (C) IPA analysis of canonical pathways upregulated in the LGG-treated neonates. Significance P-values were
calculated based on the Fisher’s right tailed exact test. The log (p-value) are shown on the x-axis of the bar chart. The color of
the bars indicates the activity (orange bars) or the inhibition (blue bars) of the predicted pathways. (D) IPA Top upstream
regulators of gene expression in LGG-treated neonates versus uninfected neonates.
https://doi.org/10.1371/journal.ppat.1008072.g004
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genes were induced upon influenza virus infection by 24 hours compared to 12 hours (75 and
16 significant differentially expressed genes, respectively, (Fig 6A), which demonstrates that
the neonatal animal has begun to upregulate important inflammatory pathways. Of these, 8
genes were only differentially expressed in infection without probiotic treatment (red
Fig 5. Sham-treated neonates begin to respond 24 hours post-infection. LGG or sham treated animals were either
mock or influenza infected on Day 3 of life. Animals were harvested 24 hours post-infection. Nanostring gene
transcription analysis was performed on whole lungs. (A) Heatmap of all genes assayed in the LGG-treated neonates,
compared to expression in all other groups. Green: Up regulated; Brown: Down regulated. N = 3 per group. (B) Principal
component analysis of both 12 and 24 hours post infection samples.
https://doi.org/10.1371/journal.ppat.1008072.g005
Fig 6. LGG treatment alone is responsible for induction of inflammatory genes. Neonatal animals were given either LGG or sham
treatment, and then infected with influenza or sham on the Day 3 of life. Animals were harvested 24 hours post-infection. Nanostring gene
transcription analysis was performed on lungs. MA plot of all genes tested at 24 hours post-infection, with (A) sham-treated influenza
infected neonates compared to uninfected neonates; (B) LGG-treated uninfected neonates compared to uninfected neonates; (C) LGG-
treated infected neonates compared to LGG-treated uninfected neonates; and (D) LGG-treated infected neonates compared to sham-treated
infected neonates. Triangles denote statistical significance (p<0.05). Red: genes unique to infections; blue: genes unique to probiotic
treatment; green: genes that are expressed by both probiotic and influenza infected animals independently; gold: interaction effect of LGG and
influenza.
https://doi.org/10.1371/journal.ppat.1008072.g006
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triangles), whereas 67 genes were also differentially expressed with probiotic treatment alone
(green and gold triangles). When neonates which receive LGG without influenza virus infec-
tion were compared to uninfected neonatal animals, 357 genes showed significant differential
expression (Fig 6B). Of these, 290 genes were specifically induced by the probiotic (blue trian-
gles, along with the 67 induced by both viral infection and probiotic treatment alone (green
and gold triangles). In sharp contrast, only 3 genes were differentially expressed between LGG
treatment alone and virally infected neonates pre-treated with LGG (Fig 6C), notably the
downregulated gene, CAMP, encoding Catheliciden Antimicrobial Peptide, which plays a role
in antimicrobial defenses and leads to activation of an inflammatory response[34].
Finally, genes were identified showing a significant interaction effect between influenza
infection and LGG treatment, whereby the contributions of infection or treatment alone do
not additively predict their combination (Fig 6D). There were 32 genes upregulated by influ-
enza infection alone (Fig 6A, gold triangles) and LGG treatment alone (Fig 6B, gold triangles).
However, neonates pretreated with LGG prior to infection had dampened induction of these
32 genes, which accounted for all of the significant interaction effects (Fig 6D, gold triangles).
The 32 genes with their associated functions are in S3 Table. Canonical pathway analysis was
completed with Ingenuity Pathway Analysis (IPA) based on these 32 genes and the 72 differen-
tially expressed genes in sham-infected neonates relative to uninfected age-matched neonates
at 24 hours post-infection. This analysis revealed one pathway which was down-regulated in
LGG-treated infected neonates and upregulated in sham-treated infected neonates: “Nitric
oxide and Reactive Oxygen Species in Macrophages”. Taken together, these results demon-
strate the neonatal inability to respond to influenza during early infection in the absence of
LGG treatment. LGG restores an adult-like transcriptome to neonates in this infection model.
LGG promotes early transcription of Type I IFNs
Based on this transcriptional analysis and LGG-induced interferon signaling, we hypothesized
that LGG promoted an early burst of type I IFNs prior to infection which contributed to
improved survival. To examine this, uninfected mice were given one dose of LGG, and lungs
were harvested at different time points, from 2 hours to 48 hours post-LGG treatment. Real
time PCR was performed to determine differences in transcription of IFNα4 and IFNβ1. We
found that there is a clear spike in transcription of these type I IFNs at 3 to 4 hours post-LGG,
which diminishes by 24 hours (Fig 7A and 7B). These data provide evidence that LGG prompts
production of type I IFNs prior to influenza infection, which modulates the type I IFN pathway
and induces an antiviral state within the lung.
Type I IFN pretreatment is sufficient to protect neonatal mice
Our transcriptional data indicated an unresponsiveness to influenza virus in neonates and
LGG-induced upregulation of type I IFN genes, which suggested early induction of type I IFN
could be mediating the protective effect of LGG. To answer this question, mice were treated
with 1000 units of recombinant IFNβ intranasally before influenza virus infection on days 1
and 2 of life, and then infected on day 3 of life. With this pretreatment, mice had improved
survival to 40% (p<0.01) (Fig 7C). This indicated that early type I IFN induction is sufficient
to confer protection to neonatal mice.
Neonatal protection by Lactobacillus rhamnosus is TLR dependent
We next examined whether LGG was acting via pattern recognition receptor (PRR) pathways
such as the Toll-like receptors (TLRs) [35] or the inflammasome [36]. To test TLR involve-
ment, neonatal mice deficient for the adaptor protein myeloid differentiation factor (MyD88)
Influenza virus infected neonates are protected by intranasal Lactobacillus rhamnosus GG treatment
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were used, as MyD88-/- animals cannot signal through the TLR pathway, with the exception of
TLR3 [37]. We performed LGG pretreatment followed by influenza virus infection in
MyD88-/- and wild type neonatal mice and compared the survival of LGG- and sham-treated
mice. We found that LGG protection in neonatal mice was abrogated when MyD88 was
absent, which demonstrated that LGG recognition is MyD88 dependent (Fig 8A). In addition,
neonatal mice were similarly sensitive to influenza virus infection without TLR signaling,
which demonstrated that neonatal mortality is TLR signaling independent.
Activation of MyD88-dependent signaling requires downstream signaling cascades such as
the MAPK pathway[38], whereby TLR activation leads to phosphorylation of tyrosine kinases
such as stress-activated protein kinase/Jun-amino-terminal kinase (SAPK/JNK). As a surro-
gate for MAPK pathway activation, we examined phosphorylation levels of SAPK/JNK in a
human alveolar epithelial cell line, A549. Cells were incubated with LGG and control media
(MRS broth) for various times or treated with LPS or UV light, as positive controls. Cell lysates
were used for immunoblotting for SAPK/pJNK. LGG-treated A549 cells demonstrated an
increase in SAPK/JNK phosphorylation as early as 15 minutes compared to sham-treated cells,
which indicated a rapid activation of downstream TLR pathways (Fig 8B and 8C).
To determine if another PRR, the inflammasome, was important for LGG protection, we
tested LGG treatment in caspase-1 deficient mice (casp1-/-), which cannot signal through the
inflammasome [39]. We found that influenza virus mortality of neonatal mice was indepen-
dent of caspase-1 and that LGG continued to protect neonatal casp1-/- mice (54% LGG versus
25% sham, p<0.05), thus excluding inflammasome involvement in both influenza virus-
induced lethality and in the protective effect of LGG (Fig 8D). Finally, to determine the role of
specific TLRs in the recognition of LGG, we used neonatal mice deficient in TLR4 (TLR4-/-),
which is known to recognize bacterial components such as LPS [40], and has been shown to
protect mice from influenza virus infection [41]. We performed LGG pretreatment and PR8
infection of TLR4-/- and C57BL/6 mice and found that LGG protection was abrogated when
TLR4 was absent (35% LGG versus 24% sham, p = 0.21; Fig 8E). While the canonical agonist
for the TLR4 receptor is bacterial LPS, human and murine neonatal TLR responses differ from
those of adults [42], with an increase in adult-like function during the first year of life [43].
There is a promiscuity in neonatal TLR in the ligands they respond to as well as intracellular
Fig 7. LGG promotes early transcription of Type I IFNs and survival of influenza virus-infected neonatal mice improves
with IFNβ pretreatment. Mouse pups received 1 x106 Colony Forming Units of LGG or sham intranasally on Day 1 of life
and then harvested at various time points. Real time PCR was performed for (A) IFNα4 and (B) IFNβ1. N = 3–9 per time
point, 3 experiments. (C) Low dose IFNβ or sham treatment was given on Days of 1 and 2 of life. Animals were infected with
influenza virus and tracked for survival. Kaplan-Meier survival statistics were completed for all experiments. (n = 15 per group,
3 experiments).
https://doi.org/10.1371/journal.ppat.1008072.g007
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crosstalk of their signaling [44]. Together, these studies highlight the protective effect of LGG
is dependent upon a TLR4-MyD88 pathway in influenza virus-infected neonates.
Heat-killed LGG is equally protective excluding colonization as a
mechanism of LGG protection
When mice are given antibiotics prior to viral [9, 14] and bacterial [45] infection, the host is
more susceptible, indicating that loss of commensal colonization on the mucosal surfaces
leaves the host more vulnerable to infection. Therefore, we questioned if LGG colonization
was required for protection of the neonatal animals. To test this, we examined whether giving
the pups heat-killed bacteria would be as equally efficacious as live LGG. Previously, others
have demonstrated a dose-response with heat-killed Lactobacillus [11]. Therefore, neonatal
pups were given a larger dose of heat-killed LGG (1x108CFU) on the first and second day of
life and infected with influenza on the third day of life, similar to the live LGG treatment proto-
col. We found the pups were equally protected when given heat-killed LGG (p<0.01) (Fig 8F),
indicating that colonization of the respiratory tract is not required for protection, but rather
mucosal priming of the respiratory tract by a component of the LGG is important for
protection.
Discussion
Immediately following birth, neonates move from the sterile in utero environment to the exter-
nal world, where they are exposed to many microorganisms, where tolerance is required to
permit commensal colonization [46]. However, this tolerogenic environment can lead to a
hyporesponsiveness to pathogenic organisms [47]. During this critical period, the neonate is
Fig 8. Heat-killed LGG provides equivalent protection and Toll like receptor signaling is critical for the recognition of Lactobacillus. (A)
MyD88-/- and C57BL/6 pups received 1 x106 Colony Forming Units of LGG intranasally on Days 1 and 2 of life. On Day 3, pups were infected
intranasally with PR-8 influenza, and survival was monitored. (p = 0.84, comparing the two MyD88-/- groups) (B) A549 cells were treated with
indicated conditions and proteins were isolated for a western blot of p-SAPK/JNK. (C) Quantification of phosphorylation of pSAPK/JNK
compared to untreated control. A similar treatment and infection protocol was followed for (D) Casp1-/- (E) TLR4-/-. N = 14–18 in each group
from 4 independent experiments. (F) Mice were given 1 x108 Colony Forming Units of heat-killed LGG intranasally on Days 1 and 2 of life, and
then infected with influenza on the third day of life; survival was monitored. n = 17 per group from 4 independent experiments.
https://doi.org/10.1371/journal.ppat.1008072.g008
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unresponsive to respiratory viral infections. We demonstrate transcriptional paralysis in the
neonatal mouse when infected with influenza virus. Twelve hours after infection, the neonatal
mouse has a similar transcriptional profile to an uninfected mouse. The transcriptional
response begins around 24-hours post infection, albeit with much less differentially expressed
genes compared to LGG-treated neonates or adults. In addition, sham-treated influenza
infected neonates have a different phenotypic response with a lack of early neutrophil recruit-
ment at the site of infection. Potentially, the increase in morbidity and mortality associated
with respiratory viral infections in neonates could be attributed to this kinetic shift in the anti-
viral response. To our knowledge, this is the first demonstration of an intranasal probiotic pre-
treatment improving survival after a respiratory viral infection in a neonatal animal model.
In contrast, there are profound transcriptional changes after influenza virus infection in
adult mice [48] and humans [49]. Neonatal mice treated with Lactobacillus rhamnosus (LGG)
prior to influenza virus infection can overcome this transcriptional unresponsiveness and are
better equipped to combat the viral infection, as demonstrated by decreased early viral loads
and improved survival. In addition, there are 32 genes down-regulated in LGG-treated influ-
enza infected neonates, compared to sham-treated influenza treated neonates (Fig 6, S3 Table),
and canonical pathway analysis revealed one pathway down-regulated in those animals which
received LGG prior to influenza infection, Nitric oxide and Reactive Oxygen Species in macro-
phages. Virus-induced oxidative stress may contribute to several aspects of pathogenesis of
influenza virus infection, including tissue damage, inflammatory response, and apoptosis[50].
The oxidative stress and damage induced during influenza virus infection is expected to be
even greater in neonatal mice as it would exacerbate the oxidative stress known to be present
in newborns [51]. Thus, newborns may be especially susceptible to the deleterious effects of
oxidative stress. We speculate that reactive oxygen species, coupled with the neonatal inability
to neutralize reactive oxygen species, could increase lung pathology in this vulnerable
population.
Until recently, the lung was considered sterile in healthy individuals. Knowledge of the
respiratory tract microbiota has changed dramatically over the past decade, with the advent of
next generation sequencing. The composition of lung microbial communities has been associ-
ated with protection and plays a beneficial role in both allergic and infectious airway diseases
[52, 53]. Recently, the importance of respiratory tract commensal colonization was demon-
strated in a cohort of premature infants; colonization with Lactobacillus early after birth was
associated with a decrease in bronchopulmonary dysplasia, a chronic lung disease of prematu-
rity [54]. Similarly, oral probiotic treatment also reduces sepsis in term, healthy neonates [55].
Clinical epidemiologic observations further suggest that the immune effects of early-life micro-
bial exposure persist into later life [13].
The role of the respiratory microbiome in health and disease is supported by studies using
intranasal administration of Lactobacillus to ameliorate the symptoms of respiratory viral
infection or allergic disease [10, 26, 27, 56]. In addition to the direct stimulation of pattern rec-
ognition receptors (PRRs) by commensal bacteria, metabolites of commensal bacteria can be
protective during influenza infection and pulmonary allergic disease [57, 58]. Such signals
could, however, be absent from neonates that have not been colonized yet with a lung micro-
biome. This quickly changes over the first few days as newborn mice already at 5 days of life
have colonized their lung microbiome [59]. Although colonization may provide a steady anti-
viral state in the lung, we show that inactivated LGG is sufficient to protect neonatal mice indi-
cating that colonization is not required. Presumably, in the human setting, colonization would
provide a long-term benefit as the effect of LGG administration diminishes with time.
PRRs that recognize gram positive bacteria and their components are considered important
in Lactobacillus-mediated priming in the lung. The specific PRR utilized, however, might be
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different depending on the probiotic. For example, peptidoglycan from the L. salivarius strain
Ls33 protected mice from chemical colitis in a nucleotide oligomerization domain (NOD)
2-dependent, MyD88-independent fashion [60], and Lactobacillus plantarum protection dur-
ing Pneumonia Virus of Mice (PVM) infection was also found to be MyD88 independent [18].
However, others have found a direct link between MyD88 and Lactobacillus species [35].
Although originally described as receptors for bacteria and fungi, TLRs have become known as
mediators of cytokine production in response to a variety of viruses and viral ligands. To test
the role of TLRs in LGG recognition in neonatal animals, we undertook a series of survival
experiments with mice devoid of the universal TLR adaptor protein MyD88 (MyD88-/-). In
MyD88-/- mice, LGG confers no protection, which implicates TLRs as the potential mecha-
nism by which LGG provides neonatal mice protection. In contrast, Caspase-1 deficient neo-
natal mice, which have no inflammasome signaling, are still protected from influenza virus by
LGG, excluding a role for the inflammasome. Further investigations into specific TLRs
revealed that TLR4 is critical for the recognition of LGG. Interestingly, there are known differ-
ences in the function of TLR4 in the neonates[42, 61, 62]. Neonatal TLRs display promiscuity
in their activating ligands[42] whereby a ligand is able to activate non-canonical receptors and
induce varying effector functions[42]. LGG could modulate TLR4 and its downstream path-
ways[63–67]. LGG-treated intestinal epithelial cells have a lower inflammatory profile, espe-
cially lower levels of IL6 and IL8 [63], consistent with our findings. In addition, activation of
TLR4 is important for induction of the Type I IFN responses and signaling [68].
Influenza virus has been shown to trigger type I IFN through recognition by TLR3, TLR7/8
and retinoic acid-inducible gene I-like receptors (RIG-I) in dendritic cells and alveolar epithe-
lial cells [69]. IFNs are produced by virus-infected epithelial cells and induce an anti-viral state
in cells receiving an IFN signal. Interferons, such as type I interferons (i.e., interferon-α, (IFN-
α) and IFN-β) and type III interferons (i.e., IFN-λ2 and IFN-λ3 in mice; collectively called
IFN-λ), are essential in antiviral defense [70–73]. Our in vivo experiments demonstrated that
pretreatment with IFNβ protected neonatal mice during influenza virus infection, congruent
with an infant mouse model of RSV infection [74]. Previous work demonstrated probiotic
stimulated type I IFN production [75]; indeed, we found that LGG stimulated type I IFN tran-
scription within hours of LGG treatment in murine neonates.
Innate response to influenza virus relies on pattern recognition molecules, like C-type lec-
tins, RIG-I, TLRs and NOD-like receptors (NLRs) [76]. As compared to adults, the immune
system of newborns is characterized by skewed TLR-mediated cytokine production, with
impaired production of Th1-polarizing cytokines such as tumor necrosis factor and IL-12p70,
but robust production of Th2/Th17-polarizing IL-6 [42, 77, 78]. TLR dimerization leads to the
activation of nuclear factor-κB (NF-κB) and interferon-regulatory factors (IRFs), and these
transcription factors in turn induce the production of proinflammatory cytokines and type I
interferons (IFNs), respectively [79, 80]. There is conflicting data about which cell type is the
source of type I IFNs during respiratory viral infection: epithelial cells, fibroblasts, plasmacy-
toid dendritic cells (pDCs), alveolar macrophages (AMs), and conventional DCs have all been
shown to produce type I IFNs after virus exposure in vitro [81–85]. A primary reason for the
conflicting data is that type I IFNs are made transiently and are difficult to detect in vivo [86].
As the immune system’s sentinel, pDCs differ drastically from conventional dendritic cells as
they uniquely express TLR7 and TLR9. This exclusive TLR repertoire expression enables pDCs
to be specialized in microbial nucleic acid sensing: TLR7 ligands include the poly-U ssRNA
from influenza virus, whereas CpG dinucleotides, which are abundant in bacterial DNA,
potently activate TLR9. pDCs serve as an important component of recognizing both viruses
and bacteria and are an intriguing cell type which might be bridging the gap between probiotic
treatment and viral infection. Potentially, there is early priming of pDCs by the inhaled
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probiotic; when the pup is exposed to virus, this important anti-viral cell type is already on the
“front-line” and ready to produce large amounts of type I IFN. However, AMs have also been
implicated in the production of type I IFNs and the subsequent recruitment of antiviral mono-
cytes [86]. Although pDCs at the cellular level produce a hundred times more type I IFNs than
other immune cells [87], they comprise a very small percentage of the cells at the site of influ-
enza or RSV infection, particularly compared to the tissue resident macrophages, the AMs.
Therefore, LGG may be acting on any of the above cell types to induce early type I IFN and
promote an antiviral state that results in reduced viral loads early in infection.
Here, we report that neonatal mice exhibit an early lung transcriptional unresponsiveness
at 12 hours post-infection, which begins to resolve by 24 hours post-infection, demonstrating
a delay in the kinetics of the neonatal antiviral response. We show that a brief, two-day course
of intranasal LGG prior to influenza virus infection protects neonatal mice from the mortality
associated with infection. Transcriptional analysis reveals LGG pretreatment of neonates
restores the lung transcriptional signature induced by infection to an adult-like profile. LGG-
mediated protection is MyD88-dependent and specifically TLR4 dependent. Importantly,
pups are equally protected when given heat-killed LGG, indicating that colonization of the
respiratory tract is not required for protection, but primes the respiratory mucosa for a robust
anti-influenza response. Future studies should determine the specific LGG components which
stimulate type I IFN transcription and recognition by TLR4.
Methods
Mice, infections and Interferon β treatment
Eight-week old adult C57BL/6 mice were purchased from Charles River Laboratory to use as
adult controls and for in-house breeding. MyD88-/- (B6.129P2(SJL)-Myd88tm1.1Defr/J), Caspase
1-/- (B6N.129S2-Casp1tm1Flv/J), and TLR4-/- (B6(Cg)-Tlr4tm1.2Karp/J) mice were purchased
from Jackson Laboratories. Experimental pups were obtained by timed mating in-house. The
mice were housed under specific-pathogen-free conditions in an American Association for the
Accreditation of Laboratory Animal Care-certified barrier facility at both the Drexel Univer-
sity College of Medicine Queen Lane Campus and New College Building animal facilities.
Neonatal mice at 3 days of age (weight ~3g) were infected intranasally (i.n.) with 0.12
TCID50 (0.04 TCID50 /g) of influenza virus H1N1 strain PR8 (A/Puerto Rico/8/34) in a 5 μl
volume. Neonatal mice at 7 days of age (weight ~5g) were infected intranasally (i.n.) with 0.20
TCID50 (0.04 TCID50 /g) of influenza virus in a 7 μl volume. Adult 8-week old C57BL/6 mice
(weight ~20g) were infected i.n. with a sublethal dose of 3 TCID50 in a 20 μl volume (0.15
TCID50 /g). The mice were anesthetized with inhaled isoflurane before intranasal inoculations.
The pups were inspected daily for their activity level, respiratory rate, and the maternal inter-
action. If the pups were noted to be ignored/disregarded by the mother, had labored/fast
breathing, weight loss, or lack of movement when handled, they were removed from the cage.
However, majority of the pups did not exhibit signs of morbidity and were not found in the
cage, assumed to be cannibalized by the mother.
Neonatal mice at 1 and 2 days of age were treated intranasally with 1,000 units of recombi-
nant mouse Interferon β (Sigma-Aldrich, I9032). Recombinant IFN β was diluted in normal
saline to 200 units per μl and 5 μl was administered intranasally under inhaled isoflurane
anesthesia.
Lactobacillus growth
LGG (ATCC 53103) was supplied by Valio Ltd (Helsinki, Finland) and cultured at 37˚C for 16
hours in MRS broth (Lactobacillus broth according to De Man, Rogosa and Sharpe) (Becton,
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Dickinson & Co., Sparks, MD, USA). Mice were intranasally administered 5 μl LGG solution
at a concentration of 1x106 CFU once daily for two consecutive days. LGG was heat inactivated
by heating to 95˚C for 30 minutes and washed with PBS. Mice were intranasally administered
5 μl LGG solution at a concentration of 1x108 CFU once daily for two consecutive days.
Viral loads
At various time points post-infection, the lungs of the mice were harvested, weighed, and frozen
at −80˚C in TRIzol (Invitrogen). RNA was isolated by the Qiagen RNeasy kit (Qiagen). The iso-
lated RNA was then used for cDNA synthesis using the High Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems). Virus was measured by real-time PCR using influenza
specific primers as previously described [88]. cDNA synthesis was performed using both a spe-
cific primer (50-TCTAACCGAGGTCGAAACGTA-30) and random hexamers. Real-time assays
were performed in triplicate with 5 μl of cDNA, 12.5 μl of 2× TaqMan Universal PCR Master
Mix (Applied Biosystems), 900 nM influenza A virus sense primer (50-AAGACCAATCCTGT
CACCTCTGA-30), 900 nM influenza A virus antisense primer (50-CAAAGCGTCTACGCTG
CAGTCC-30), and 200 nM influenza A virus probe (FAM-50-TTTGTGTTCACGCTCACCG
T-30-TAMRA) [89]. All primers were specific for the influenza A virus matrix protein. Amplifi-
cation and detection were performed using an Applied Biosystems Prism 7900HT sequence
detection system with SDS 2.2.1 software (Applied Biosystems) at the following conditions: 2
min at 50˚C and 10 min at 95˚C, then 45 cycles of 15 s at 95˚C and 1 min at 60˚C. For viral load
measurement, a standard curve was developed with serial 10-fold dilutions of stock PR8 with a
known TCID50 concentration. Ct values were plotted against virus quantity in TCID50 per milli-
liter. This curve was used to convert the Ct values for viral loads to TCID50 equivalents. Virus
RNA quantities in lungs were expressed as TCID50 equivalents/100 mg lung.
Quantitative reverse transcription (RT)-PCR
At different points during infection, the right lobes of infected lungs were harvested and imme-
diately homogenized in Tri Reagent (AB Applied Biosciences [AB]). Total RNA purification was
carried out using the RiboPure kit (AB). Conversion into cDNA used the TaqMan RNA-to-
CTT 2-step kit (AB). TaqMan quantitation of alpha 4 interferon (IFN-α4), beta 1 interferon
(IFN-β1), gamma interferon (IFN-γ) IL-6, and GAPDH was carried out with inventoried prim-
ers in an AB 7900HT sequence detection system according to the manufacturer’s instructions.
For relative quantitation of the different mRNA species, all values were normalized to measured
levels of GAPDH transcripts and expressed relative to values for uninfected WT mice using the
comparative threshold cycle (CT) method (Applied Biosystems, Guide to performing relative
quantitation of gene expression using real-time quantitative PCR, part number 4371095, rev. B).
Isolation of pulmonary cells and Flow Cytometry
Pulmonary lymphocytes were isolated from individual mice by removing lungs and mincing
into smaller pieces. The tissue was then digested for 2 h at 37˚C with 3.0 mg/ml collagenase A
and 0.15 μg/ml DNase I (Roche) in RPMI 1640 (Mediatech) containing 5% heat-inactivated FBS
(Life Technologies), 2 mM l-glutamine, 100 IU/ml penicillin, 100 μg/ml streptomycin (Media-
tech). The digested tissue was then passed through a 40-μm cell strainer (Falcon) and washed in
the same media as above. Cells were counted using trypan blue exclusion with light microscopy.
Cells were co-stained with anti-mouse CD45 conjugated to PerCP Cy5.5 (Biolegend),
CD11c conjugated to PE-Texas Red (Biolegend), CD11b conjugated to APC (Biolegend),
Ly6G conjugated to Pacific Blue (Biolegend), MHCII conjugated to FITC (ThermoFisher),
SiglecF conjugated to PE (Biolegend). All stains were completed on ice to prevent
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internalization. All absolute cell numbers are calculated per 100 mg of lung tissue. Cells were
fixed in 1% paraformaldehyde (Fisher Scientific) before flow cytometric analysis. Data were
collected on a FACS Fortessa using FACS Diva software (BD Biosciences). Analysis was per-
formed using Flow Jo software (Tree Star).
Histopathology
After lavage, the left lobe of the lung was inflated and fixed with 0.5 ml of 4% neutral-buffered
formalin solution. Deparaffinized sections from fixed lungs were stained with hematoxylin
and eosin (H&E). Lung infiltration was scored blindly by a board-certified pathologist. An
intensity score in each of two categories was determined: peribronchiolotis (0 none to 5 severe)
and alveolitis (0 none to 5 severe). A weighted intensity score was then determined based on
the percentage of lung involvement.
RNA isolation and Nanostring nCounter PanCancer Immune Profiling for
Mouse
Total RNA was isolated from adult and neonatal lungs 12-hour post PR8 virus infection using
RNeasy kit (Qiagen) and quantified using a ND-1000 sprectrophotometer (ThermoScientific).
50 ng of RNA was used per sample and diluted to 5 μL total using RNase free water for Pan-
Cancer Immune Profiling for Mouse (Nanostring). Samples were then processed according to
nCounter Gene Expression Assay Protocol. In brief, 8 μL of master mix containing a hybrid-
ization buffer and Reporter CodeSet were added to each 5μL sample. 2 μL of Capture ProbeSet
was then added to each sample, tubes were spun down and incubated overnight at 65˚C in a
pre-heated C1000 Touch Thermal Cycler (Bio-Rad). Samples were then quantified based on
number of target probes using nCounter Digital Analyzer High Sensitivity setting and ana-
lyzed using nSolver software. Downstream analysis used exported count tables to identify dif-
ferentially expressed genes applied the DESeq2 [90] [91]v 1.22.2) package, using counts of the
NanoString house-keeping genes as “negative” control genes during estimation of size factors.
In pairwise comparisons, Wald tests were used to measure statistical significance using an
FDR-corrected p-value cut-off of 0.05. To measure non-additive interactions in gene expres-
sion with viral infection and probiotic treatment, likelihood ratio tests were performed, mea-
suring the effect of including an infection:probiotic interaction term.
Pathway analysis
Significantly upregulated and downregulated genes in whole lung lysate at 12 and 24 hours
post influenza infection were determined based on a False Discovery Rate of<0.05 and greater
than a 2-fold difference. Their fold-change values were uploaded into Ingenuity Pathway Anal-
ysis (IPA)(Qiagen). IPA analysis identified canonical pathways and upstream regulators pre-
dicted to be affected by the upregulated and downregulated genes. Blue indicates
downregulated genes; orange indicates upregulated genes.
Immunoblotting
For detection of pSAPK/JNK proteins, cells were seeded into a 6-well dish at 1x106 cell per
well and allow to rest overnight at 37˚C in 5%CO2 incubator. LGG was grown as described
previously. Cells were treated with LGG, Sham, LPS 100ng/ml, or UV light for the indicated
amount of time. Cell monolayers were washed twice with PBS and whole cell lysates were
obtained using RIPA buffer containing protease and phosphatase inhibitors (Cell Signaling
Technology, 5872). Proteins were resolved in 5–20% gradient SDS-PAGE, then transferred to
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PVDF membranes for western blotting. Antibodies directed against the following proteins
were used: Phospho-SAPK/JNK (Thr183/Tyr185) (Cell Signaling Technology, 4668), SAPK/
JNK (Cell Signaling Technology, 9252) and Histone H3 (Cell Signaling Technology, 4499).
Goat-anti-rabbit horseradish peroxidase conjugated secondary antibody was used for indirect
detection of target proteins.
Statistical analysis
Statistical analysis was performed using the Shapiro-Wilk W test for normality, Student’s t-test
and nonparametric Wilcoxon signed-rank test for paired and unpaired samples, log-rank test
for survival curves. Analyses were performed with the JMP statistical analysis program (SAS,
Cary, NC). P values<0.05 were considered to be statistically significant.
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